logo

BNTX

BioNTech·NASDAQ
--
--(--)
--
--(--)
4.66 / 10
Netural

Fundamental assessment is balanced (score 4.7/10). Strengths include high gross profit margin (84.28%) and positive PB-ROE (0.1014). Weaknesses are low current and fixed assets turnover ratios, indicating inefficiency in utilizing current and fixed assets. Net profit margin is high at 100.94%, but overall factor performance is mixed, leading to a neutral stance.

Fundamental(4.66)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-0.19
Score2/3
Weight24.15%
1M Return11.69%
Inventory turnover ratio
Value1.21
Score2/3
Weight-4.02%
1M Return-2.63%
Gross profit margin (%)
Value84.28
Score2/3
Weight2.62%
1M Return1.47%
Profit-MV
Value0.46
Score2/3
Weight15.85%
1M Return7.79%
PB-ROE
Value0.10
Score1/3
Weight14.63%
1M Return7.02%
Current assets turnover ratio
Value0.11
Score0/3
Weight-2.90%
1M Return-1.88%
Fixed assets turnover ratio
Value1.99
Score1/3
Weight-2.51%
1M Return-1.64%
Asset-MV
Value-0.50
Score3/3
Weight36.78%
1M Return14.99%
Cash-MV
Value0.64
Score2/3
Weight15.87%
1M Return7.73%
Net profit / Total profit (%)
Value100.94
Score0/3
Weight-0.47%
1M Return-0.30%
Is BNTX undervalued or overvalued?
  • BNTX scores 4.66/10 on fundamentals and holds a Fair valuation at present. Backed by its -4.39% ROE, -18.57% net margin, -43.61 P/E ratio, 1.27 P/B ratio, and -28.38% earnings growth, these metrics solidify its Netural investment rating.